TORONTO, Aug. 16, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the Patent Cooperation Treaty (“PCT”) has published…


Previous articlePsychedelic Medicine Virtual Symposium – 8/28, 9/11, 9/25
Next articlePsychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin A